vantictumab

Ligand id: 10197

Name: vantictumab

Classification
Compound class Antibody
Comments
Vantictumab (OMP-18R5) is an anti-FZD antagonistic monoclonal that induces inhibition of the Wnt signalling pathway [2]. It is being developed by OncoMed Pharmaceuticals. As receptors for Wnt ligands the FZD receptors are molecular targets for the prevention and treatment of cancer and inflammation that lie upstream of β‑catenin. Inhibition of Wnt-induced FZD activation by vantictumab reduces tumour cell proliferation and in vivo tumorigenicity [1], indicating the potential utility of blocking the activation of selected members of the FZD receptor family as a treatment for a wide range of tumours.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Database Links
Specialist databases
IMGT/mAb-DB 470
Other databases
GtoPdb PubChem SID 381118907